Clinical trial
Phase I/II Trial of Modified Vaccinia Virus Ankara (MVA) Vaccine Against…
NCT00053742 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00053742 |
|---|---|
| Title | Phase I/II Trial of Modified Vaccinia Virus Ankara (MVA) Vaccine Against Smallpox |
| Official title | A Phase I/II Clinical Trial of Modified Vaccinia Virus Ankara (MVA) to Evaluate Its Safety, Immunogenicity and Protective Efficacy Against Dryvax® (Registered Trademark) Challenge in Vaccinia-Immune Individuals |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Healthy |
| Intervention type | Drug |
| Interventions | Modified Vaccinia Virus Ankara TBC-MVA |
| Enrollment | 80 |
| Start date | Feb 1, 2003 |
| Completion | Mar 1, 2006 |
| First posted | Feb 5, 2003 |
| Last update posted | Mar 4, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: